首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

合約開發和生產組織 (CDMO) 市場規模、佔有率和成長分析（按服務、最終用戶和地區分類）- 產業預測 (2026-2033)

市場調查報告書

商品編碼

1899564

合約開發和生產組織 (CDMO) 市場規模、佔有率和成長分析（按服務、最終用戶和地區分類）- 產業預測 (2026-2033)

Pharmaceutical Contract Development and Manufacturing Market Size, Share, and Growth Analysis, By Service (Pharmaceutical Manufacturing Services, Drug Development Services), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球醫藥合約開發和生產組織 (CDMO) 市場規模預計在 2024 年達到 1501.2 億美元，從 2025 年的 1600.6 億美元成長到 2033 年的 2672.9 億美元，在預測期（2026-2033 年）複合年成長率為 6. 62%。

醫藥合約開發與生產市場透過向製藥公司提供包括成品製劑和活性藥物成分生產以及藥物研發在內的多種服務，實現了顯著成長。推動這一成長的因素包括先進技術的應用、專利到期、研發投入的增加以及對學名藥和生物製藥需求的成長。此外，人們對細胞和基因療法、個人化醫療、高效藥物成分以及抗體藥物複合體（ADC）的興趣日益濃厚，也進一步推動了市場需求。然而，序列化需求和合格人員短缺等挑戰可能會阻礙市場成長。總體而言，市場格局仍在不斷演變，反映出該行業已做好充分準備，以應對新的治療需求和技術進步。

推動全球醫藥合約開發與生產市場發展的因素

全球藥品合約研發生產市場正蓬勃發展，這主要得益於外包帶來的諸多優勢，尤其是成本和時間效率的提升。該行業的公司正大力投資基礎設施、人力資源和技術能力的提升，力求在外包收入中佔據更大的佔有率。透過策略性地提高營運效率和資源配置，這些公司能夠更好地滿足客戶需求，並實現更精簡、更具成本效益的生產流程。因此，在對專業外部合作夥伴日益成長的依賴下，藥品研發生產市場持續擴張。

全球藥品合約開發和生產市場阻礙因素

對流程理解的不足會導致產品線缺陷，從而削弱消費者信心，並危及研發商、製造商和經銷商之間的關係。這種不確定性威脅到全球醫藥合約研發生產市場的信任度，因為相關人員會因為擔心品質保證而不願合作。這反過來又會增加產品召回和負面宣傳的風險，最終影響產業的盈利和永續性。因此，加深對流程的理解對於降低這些風險、創造更穩健可靠的市場環境至關重要。

全球醫藥合約開發與生產市場趨勢

全球藥品合約開發和生產市場正呈現出顯著的發展趨勢，這主要得益於對特異性癌症治療需求的不斷成長以及藥物開發技術的進步。隨著癌症發生率的上升，人們的關注點已明顯轉向開發安全、有效且高效的新型化學實體（NCE），這些藥物具有更高的選擇性和更優的給藥方案。對標靶治療的日益關注促使製藥公司積極利用合約生產服務作為高效的生產解決方案，從而提升其將創新藥物快速推向市場的能力。因此，市場正在不斷發展以滿足這些新興需求，並專注於擴充性、柔軟性和嚴格的品質合規性。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Cambrex Corporation
Samsung Biologics Co., Ltd.
Siegfried Holdings AG
FUJIFILM Diosynth Biotechnologies
Aenova Group
Wuxi Biologics, Inc.
Aurobindo Pharma, Ltd.
Vetter Pharma International GmbH
Thermo Fisher Scientific, Inc.
Catalent, Inc
Recipharm AB
Almac Group
Lonza Group Ltd.
Piramal Enterprises Limited
Fabbrica Italiana Sintetici SpA
Fareva SA
CH Boehringer Sohn AG & Co. KG.
Jubilant Pharmova Limited
Curia Global, Inc.
Delpharm Holdings

結論與建議

簡介目錄

Product Code: SQMIG35J2034

Global Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 150.12 Billion in 2024 and is poised to grow from USD 160.06 Billion in 2025 to USD 267.29 Billion by 2033, growing at a CAGR of 6.62% during the forecast period (2026-2033).

The market for pharmaceutical contract development and manufacturing is experiencing notable growth as firms offer diverse services to pharmaceutical clients, including the production of final dosage forms, active pharmaceutical ingredients, and drug research. Factors driving this expansion include the adoption of advanced technologies, patent expirations, increased R&D investment, and heightened demand for generic medications and biologics. Additionally, the rising interest in cell and gene therapies, personalized medicines, high potency active pharmaceutical ingredients, and antibody-drug conjugates is further fueling market demand. However, challenges such as the need for serialization and a shortage of qualified professionals may hinder growth. Overall, the landscape is evolving, reflecting the industry's responsiveness to emerging therapeutic needs and technological advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Contract Development and Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Contract Development and Manufacturing Market Segments Analysis

Global Pharmaceutical Contract Development and Manufacturing Market is segmented by Service, End User and region. Based on Service, the market is segmented into Pharmaceutical Manufacturing Services, Drug Development Services, Biologics Manufacturing Services and Packaging Services. Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceutical Contract Development and Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is experiencing growth due to the myriad benefits associated with outsourcing, particularly cost and time efficiencies. Companies in this sector are eager to capture greater shares of the outsourcing revenue by investing significantly in enhancing their infrastructure, workforce, and technological capabilities. This strategic focus on improving operational efficiency and resource allocation enables these firms to better meet the demands of their clients, facilitating a more streamlined and cost-effective production process. As a result, the market continues to expand, driven by the increasing reliance on specialized external partners for pharmaceutical development and manufacturing needs.

Restraints in the Global Pharmaceutical Contract Development and Manufacturing Market

A deficiency in process comprehension can lead to flawed product lines, subsequently undermining consumer trust and jeopardizing the relationships among developers, manufacturers, and distributors. This uncertainty can diminish the overall reliability of the Global Pharmaceutical Contract Development and Manufacturing market, as stakeholders may become hesitant to engage in collaborations due to concerns over quality assurance. As a result, the potential for product recalls and negative publicity looms larger, ultimately impacting profitability and sustainability in the industry. Therefore, enhancing process understanding is crucial to mitigate these risks and foster a more robust and trustworthy market environment.

Market Trends of the Global Pharmaceutical Contract Development and Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is witnessing a significant trend driven by the escalating demand for specialized oncology treatments and advancements in drug development technology. As cancer incidence rises, there is a pronounced shift towards developing safe, effective, and highly potent New Chemical Entities (NCEs) that offer greater selectivity and improved dosing regimens. This growing interest in targeted therapies is prompting pharmaceutical companies to leverage contract services for efficient manufacturing solutions, enhancing their ability to bring innovative drugs to market swiftly. Consequently, the market is evolving with a focus on scalability, flexibility, and stringent quality compliance to meet these emerging needs.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Case Studies

Global Pharmaceutical Contract Development and Manufacturing Market Size by Service & CAGR (2026-2033)

Market Overview
Pharmaceutical Manufacturing Services
- API Manufacturing Services
- FDF Manufacturing Services
Drug Development Services
Biologics Manufacturing Services
- API Manufacturing Services
- FDF Manufacturing Services
Packaging Services

Global Pharmaceutical Contract Development and Manufacturing Market Size by End User & CAGR (2026-2033)

Market Overview
Large Pharmaceutical Companies
Small and Mid-size Pharmaceutical Companies
Generic Pharmaceutical Companies
Others

Global Pharmaceutical Contract Development and Manufacturing Market Size & CAGR (2026-2033)

North America (Service, End User)
- US
- Canada
Europe (Service, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Service, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holdings AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aenova Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wuxi Biologics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vetter Pharma International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almac Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fabbrica Italiana Sintetici S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fareva SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
C.H. Boehringer Sohn AG & Co. KG.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharmova Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delpharm Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments